We hypothesize that it is most likely that the cumulative effect of these specific gene expression differences associated with combination therapy, compared to IL-15 complex monotherapy, taken together with the significant increases in the many gene scores associated with antitumor activity following combination therapy, necessitates the enhanced tumor control and clearance of EO771 tumors observed with double treatment with IL-15 complexes and anti-PD-1 therapy. Here, IL15 is linked to neoplasm.